Known hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (patients with chronic or cleared HBV and HCV infection are eligible)
Patients must not have known active hepatitis B virus (HBV) or hepatitis virus (HCV) infection at time of registration; patients with HBV or HCV that have an undetectable viral load, or in the opinion of the treating investigator is well-controlled, are eligible
Patients with evidence of active hepatitis B virus (HBV) or hepatitis C Virus (HCV) infection are not eligible; patients with cleared HBV and HCV infection will be allowed
Patients with hepatitis C virus (HCV) infection are eligible provided they meet the other eligibility criteria and:\r\n* They have previously undergone curative therapy and have no evidence of active HCV infection\r\n* They have no evidence of liver damage owing to prior HCV infection
Active HBV or HCV infection.
Known hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (subjects with laboratory evidence of cleared HBV and/or HCV will be permitted)
Negative for active HBV and HCV at screening
Active infection (any infection requiring systemic treatment). Hepatitis B or C [HBV/HCV] is allowed
Escalation part: Active Hepatitis B (HBV) or Hepatitis C (HCV) virus infection at screening. Expansion part: Patients with active HBV or HCV are excluded, excepting those patients undergoing treatment for HBV or HCV.
Patients who have been infected with HBV or HCV including those with inactive disease.
Known chronic hepatitis B or C virus (HBV/HCV) infection
Known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (subjects with laboratory evidence of cleared HBV and HCV infection will be permitted)
Known history of hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (patients with chronic or cleared HBV and HCV infection are eligible); it is not necessary to conduct HBV and HCV testing at screening
Known history of HBV or HCV infection.
Known active HCV, HBV, and/or HIV infection.
Subjects with known active hepatitis B virus (HBV) or hepatitis C virus (HCV) (cannot have an elevated viral load of HBV or HCV if known history) are ineligible
Dual infection with HBV/HCV or other hepatitis combinations at study entry
Subject has active infection with HIV, HBV, HCV or HTLV
Known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (with the exception of chronic or cleared HBV or HCV infection, which will be allowed)
Known chronic hepatitis B or C (HBV/HCV) infection.
Active hepatitis B (HBV) or hepatitis C (HCV) infection
Has dual active HBV infection (HBsAg [+] and/or detectable HBV deoxyribonucleic acid [DNA]) and HCV infection (anti-HCV Ab [+] and detectable HCV RNA) at study entry
Known hepatitis B virus (HBV) or hepatitis C virus (HCV) infection; patients with documented cure from HCV infection will be included
No known active infection with hepatitis B virus (HBV), or hepatitis C virus (HCV). Patients with chronic or cleared HBV infection and HCV infection are eligible.
Has dual infection with HBV/HCV or other hepatitis combinations at study entry
Known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (subjects with laboratory evidence of cleared HBV and HCV infection will be permitted)
Subject has active infection with HIV, HBV, HCV or HTLV
FOR ALL PHASES (Ib AND II): Hepatitis B (HBV) or hepatitis C (HCV); all patients must be screened for HBV and HCV up to  days prior to study drug start using the routine hepatitis virus laboratorial panel
Known HIV, HBV, or HCV infection;
A history of hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (subjects with laboratory evidence of cleared HBV and/or HCV will be permitted
Known human immunodeficiency virus (HIV), hepatitis B Virus (HBV), or hepatitis C Virus (HCV) infection (subjects with laboratory evidence of cleared HBV and HCV infection will be permitted)
Known active infection with Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), or HIV. Cleared HBV/HCV infection is not an exclusion, nor is HIV infection with cluster of differentiations  (CD) counts > and an undetectable viral load.
Has known active hepatitis B without hepatitis B virus (HBV) treatment (HBV infection with ongoing HBV treatment is allowed); has persistent chronic hepatitis C infection (successfully treated hepatitis C virus [HCV] infection is allowed)
Has dual infection with HBV/HCV or other hepatitis combinations at study entry
Known history of HIV, HBV or HCV infection.
Known active hepatitis B virus (HBV), human immunodeficiency virus (HIV) or hepatitis C virus (HCV) infection (patients with chronic or cleared HBV and HCV infection, are eligible)
Known history of HIV, HBV or HCV infection.
Active hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (patients with chronic or cleared HBV and HCV infection are eligible)
A history of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection; subjects with laboratory evidence of cleared HBV and/or HCV will be allowed
Known history of HIV, HBV or HCV infection.
No known active infection with hepatitis B virus (HBV), or hepatitis C virus (HCV); patients with chronic or cleared HBV infection and HCV infection are eligible
Known hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (patients with chronic or cleared HBV and HCV infection are eligible); patients with human immunodeficiency virus (HIV) are not eligible if on anti-retroviral medications
Must not be HIV, HBV or HCV positive
Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, currently requiring medical intervention, per institutional protocol. Testing for HBV or HCV status is not necessary unless clinically indicated or the patient has a history of HBV or HCV infection requiring treatment with currently an unknown status. History of treated hepatitis is not exclusionary
Diagnosis of HIV or evidence of active HBV or HCV
Known HIV, HBV, or HCV infection.
Dual active HBV infection (HBsAg (+) and /or detectable HBV DNA) and HCV infection (anti-HCV Ab(+) and detectable HCV RNA) at study entry.
Active hepatitis B (HBV) or C (HCV) infection.
Known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection; subjects with laboratory evidence of cleared HBV and HCV infection will be permitted
Known active HIV, HBV, or HCV infection. Inactive hepatitis carrier status or low viral hepatitis titer on antivirals is allowed.
Patients with evidence of active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection are not eligible; patients with cleared HBV and HCV ( viral load) infection will be allowed
A history of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (with the exception of cleared HBV and HCV infection, which will be allowed)
Subjects who have a history of human immunodeficiency virus (HIV) infection or subjects who have an active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection requiring treatment due to a theoretical concern that the degree of immune suppression associated with the treatment may result in progression of HIV infection; subjects with chronic HBV or HCV infection are eligible at the investigators discretion if the subject is considered non-infectious based on serological markers
Known hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (patients with chronic or cleared HBV and HCV infection are eligible); patients with known human immunodeficiency virus (HIV) infection are eligible if not on antiviral agents and cluster of differentiation (CD) counts are adequate (>= )
Known hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection, which will be allowed); patients with human immunodeficiency virus (HIV) are not eligible if on anti-retroviral medications
Known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection, which will be allowed)
A history of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (with the exception of cleared HBV and HCV infection, which will be allowed)
A history of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (with the exception of cleared HBV and HCV infection, which will be allowed)
Has dual active HBV infection and HCV infection at study entry.
Known hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (patients with chronic or cleared HBV and HCV infection are eligible); patients with human immunodeficiency virus (HIV) are not eligible if on anti-retroviral medications
Patients with HBV, HCV or HIV infection
Active infection with HIV, HBV, HCV or HTLV as minimally defined below:
Known chronic hepatitis B or C virus (HBV/HCV) infection, unless comorbidity in subjects with Hepatocellular carcinoma (HCC).
For Cohort : has dual infection with HBV/Hepatitis C virus (HCV) or other hepatitis combinations at study entry
Known infection with HIV, HBV or HCV.
Known chronic hepatitis B or C (HBV/HCV) infection.
Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection per institutional protocol. Testing for HBV or HCV status is not necessary unless clinically indicated or the patient has a history of HBV or HCV infection
Has known active Hepatitis B (HBV) or Hepatitis C (HCV)
Known active HIV, HBV or HCV infection
Known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection, which will be allowed)
Any known active liver disease. For participants who are known carriers of HBV/HCV, active hepatitis B/C infection must be ruled out per local guidelines
Known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection which will be allowed)
Co-infection of HBV and HCV
Active Infection with HBV or HCV
Known hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (patients with chronic or cleared HBV and HCV infection are eligible); patients with human immunodeficiency virus (HIV) are not eligible if on anti-retroviral medications
Patients with known HIV, HBV or HCV infection (note: testing for these infections is not required).
Known HIV, HBV, HCV infection (except chronic or cleared HBV and HCV infection which will be allowed)
Active infection with HIV, HBV or HCV
Known Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) infection. Subjects with laboratory evidence of cleared HBV and HCV infection may be enrolled;
Known active hepatitis B or C. HBV and HCV tests are required prior to Day .
Active/chronic HBV or HCV infection;
Known active hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (patients with chronic or cleared HBV and HCV infection, are eligible); patients with human immunodeficiency virus (HIV) are not eligible if on anti-retroviral medications
Chronic hepatitis C virus (HCV) infection prior to study enrollment with screening laboratory results indicating HCV genotype  or  infection
Known HIV or known active HBV or HCV infection
Known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection, which will be allowed); HIV-positive patients on combination antiretroviral therapy are ineligible
Subject has a known history of acute or chronic hepatitis B (HBV), HIV or hepatitis C (HCV) infection.
Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection (subjects with laboratory evidence of cleared HBV and HCV infection will be permitted).
Known hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (patients with chronic or cleared HBV and HCV infection are eligible); patients with human immunodeficiency virus (HIV) are not eligible if on anti-retroviral medications
Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection)
A history of known Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection. Subjects with laboratory evidence of cleared HBV and HCV infection may be enrolled.
Active hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (patients with chronic or cleared HBV and HCV infection are eligible)
Known history of human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection which will be allowed)
Subject has active infection with HIV, HBV, HCV or HTLV as defined below:
Uncontrolled infection, including active human immunodeficiency virus (HIV)-, hepatitis B (hepatitis B virus [HBV]) and/or hepatitis C (hepatitis C virus [HCV]) infection (positive HBV or HCV viral load in the setting of positive HBV core antibody or surface antibody or HCV antibody); history of HBV or HCV is allowed if there is no uncontrolled viral infection; patients with any active viral infection are excluded
Evidence of prior hepatitis B (HBV) or hepatitis C (HCV)
Subjects with known HIV infection, chronic active hepatitis B or C virus (HBV/HCV) infection.
Known hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (patients with chronic or cleared HBV and HCV infection are eligible); patients with human immunodeficiency virus (HIV) are not eligible if on anti-retroviral medications
Known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection which will be allowed)
Known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (subjects with laboratory evidence of cleared HBV and HCV infection will be permitted)
Known hepatitis B or C virus (HBV or HCV) infection, unless the patient has been cleared for chemotherapy from experts on viral hepatitis (infectious disease specialists or hepatologists)
Known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection which will be allowed)
Known human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) infection (Exception: Subjects with chronic or cleared HBV and HCV infection and stable liver function tests [bilirubin, AST] will be allowed)
Has active hepatitis B (HBV) or hepatitis C (HCV).